Technical Analysis for CELG - Celgene Corporation

Grade Last Price % Change Price Change
grade B 108.24 0.10% 0.11
CELG closed up 0.1 percent on Wednesday, November 20, 2019, on 22.59 times normal volume.
Earnings due: Apr 23
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Down
Historical CELG trend table...

Date Alert Name Type % Chg

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company's commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The company's pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc.; FORMA Therapeutics Holdings; Concert Pharmaceuticals, Inc.; Array BioPharma, Inc.; and Acetylon Pharmaceuticals, Inc., as well as a strategic alliance with MorphoSys AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Medicine Chemistry Cancer Chemotherapy Acute Myeloid Leukemia Multiple Myeloma Antineoplastic Drugs Anemia Immunosuppressants Therapies For Cancer Celgene Solid Tumor Metastatic Breast Cancer Summit Aromatic Amines Cutaneous T Cell Lymphoma Myelodysplastic Syndromes Myelofibrosis PDA Ace 536 Immune Inflammatory Related Diseases Lenalidomide Pomalidomide

Is CELG a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 110.7
52 Week Low 58.59
Average Volume 8,427,248
200-Day Moving Average 95.60
50-Day Moving Average 103.23
20-Day Moving Average 108.17
10-Day Moving Average 109.43
Average True Range 1.16
ADX 50.85
+DI 29.29
-DI 19.69
Chandelier Exit (Long, 3 ATRs ) 107.23
Chandelier Exit (Short, 3 ATRs ) 107.48
Upper Bollinger Band 111.47
Lower Bollinger Band 104.88
Percent B (%b) 0.51
BandWidth 6.09
MACD Line 1.78
MACD Signal Line 2.15
MACD Histogram -0.3639
Fundamentals Value
Market Cap 84.68 Billion
Num Shares 782 Million
EPS 3.23
Price-to-Earnings (P/E) Ratio 33.51
Price-to-Sales 6.42
Price-to-Book 9.26
PEG Ratio 0.67
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 110.22
Resistance 3 (R3) 110.12 109.35 109.89
Resistance 2 (R2) 109.35 108.85 109.41 109.78
Resistance 1 (R1) 108.80 108.54 109.08 108.90 109.67
Pivot Point 108.03 108.03 108.17 108.09 108.03
Support 1 (S1) 107.48 107.53 107.76 107.58 106.81
Support 2 (S2) 106.71 107.22 106.77 106.70
Support 3 (S3) 106.16 106.71 106.59
Support 4 (S4) 106.26